During the second phase of the Gammora trial which was conducted two week after the first,
patients were given the Gammora drug with some additional Retroviral medication for another thirty to thirty-seven days.
As this happens, the reverse transcriptase, by jumping back and forth between the two different RNA templates,
will generate a newly synthesized Retroviral DNA sequence that is a recombinant between the two parental genomes.